On December 19, a German court invalidated CureVac’s messenger RNA technology patent, EP 1 857 122 B1, in a lawsuit brought by CureVac against its rival BioNTech…… By: Goodwin
Previous Story
Breaking: Judgment in Regeneron v. Mylan (aflibercept) BPCIA Case Finding Some Claims of Asserted Patents Valid and Infringed
Next Story
Retina Group of Washington Files Notice of Data Breach Affecting Over 455k Patients
